- Home
- DNP vs KYMR Comparison
DNP vs KYMR Comparison
Compare DNP & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- KYMR
- Stock Information
- Founded
- DNP 1986
- KYMR 2015
- Country
- DNP United States
- KYMR United States
- Employees
- DNP N/A
- KYMR N/A
- Industry
- DNP Investment Managers
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- DNP Finance
- KYMR Health Care
- Exchange
- DNP Nasdaq
- KYMR Nasdaq
- Market Cap
- DNP 3.6B
- KYMR 3.1B
- IPO Year
- DNP N/A
- KYMR 2020
- Fundamental
- Price
- DNP $9.84
- KYMR $45.79
- Analyst Decision
- DNP
- KYMR Strong Buy
- Analyst Count
- DNP 0
- KYMR 16
- Target Price
- DNP N/A
- KYMR $58.94
- AVG Volume (30 Days)
- DNP 517.5K
- KYMR 772.9K
- Earning Date
- DNP 01-01-0001
- KYMR 08-06-2025
- Dividend Yield
- DNP 7.93%
- KYMR N/A
- EPS Growth
- DNP N/A
- KYMR N/A
- EPS
- DNP 1.56
- KYMR N/A
- Revenue
- DNP $76,210,934.00
- KYMR $58,885,000.00
- Revenue This Year
- DNP N/A
- KYMR $58.26
- Revenue Next Year
- DNP N/A
- KYMR N/A
- P/E Ratio
- DNP $6.27
- KYMR N/A
- Revenue Growth
- DNP N/A
- KYMR N/A
- 52 Week Low
- DNP $8.69
- KYMR $19.45
- 52 Week High
- DNP $10.04
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- DNP 59.94
- KYMR 56.87
- Support Level
- DNP $9.75
- KYMR $44.11
- Resistance Level
- DNP $9.82
- KYMR $46.88
- Average True Range (ATR)
- DNP 0.07
- KYMR 1.60
- MACD
- DNP 0.01
- KYMR -0.18
- Stochastic Oscillator
- DNP 82.69
- KYMR 65.91
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.